Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.
Department of Anesthesiology
Author Title Type [ Year(Asc)]
Filters: Keyword is Atracurium  [Clear All Filters]
2014
Diaz LL, Zhang J, Heerdt PM.  2014.  Comparative pharmacodynamics of pancuronium, cisatracurium, and CW002 in rabbits.. J Am Assoc Lab Anim Sci. 53(3):283-9.
2010
Kopman AF, Lien CA, Naguib M.  2010.  Determining the potency of neuromuscular blockers: are traditional methods flawed? Br J Anaesth. 104(6):705-10.
Sunaga H, Zhang Y, Savarese JJ, Emala CW.  2010.  Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs.. Anesthesiology. 112(4):892-9.
Savarese JJ, McGilvra JD, Sunaga H, Belmont MR, Van Ornum SG, Savard PM, Heerdt PM.  2010.  Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011.. Anesthesiology. 113(1):58-73.
2009
Lien CA, Savard P, Belmont M, Sunaga H, Savarese JJ.  2009.  Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine.. J Crit Care. 24(1):50-7.
2005
Kopman AF, Kopman DJ, Ng J, Zank LM.  2005.  Antagonism of profound cisatracurium and rocuronium block: the role of objective assessment of neuromuscular function.. J Clin Anesth. 17(1):30-5.
2003
Suzuki T, Lien CA, Belmont MR, Tjan J, Savarese JJ.  2003.  Edrophonium effectively antagonizes neuromuscular block at the laryngeal adductors induced by rapacuronium, rocuronium and cisatracurium, but not mivacurium.. Can J Anaesth. 50(9):879-85.
1999
Kopman AF, Klewicka MM, Kopman DJ, Neuman GG.  1999.  Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short, and ultrashort duration.. Anesthesiology. 90(2):425-31.
1997
Savarese JJ, Lien CA, Belmont MR, Wastila WB.  1997.  [The clinical pharmacology of new benzylisoquinoline-diester compounds, with special consideration of cisatracurium and mivacurium].. Anaesthesist. 46(10):840-9.
1996
Wastila WB, Maehr RB, Turner GL, Hill DA, Savarese JJ.  1996.  Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats.. Anesthesiology. 85(1):169-77.
Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR.  1996.  Importance of the organ-independent elimination of cisatracurium.. Anesth Analg. 83(5):1065-71.
Ornstein E, Lien CA, Matteo RS, Ostapkovich ND, Diaz J, Wolf KB.  1996.  Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients.. Anesthesiology. 84(3):520-5.
Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ.  1996.  Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia.. Anesthesiology. 84(2):300-8.
1995
Lien CA, Belmont MR, Abalos A, Eppich L, Quessy S, Abou-Donia MM, Savarese JJ.  1995.  The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.. Anesthesiology. 82(5):1131-8.
Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ.  1995.  The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.. Anesthesiology. 82(5):1139-45.
Savarese JJ, Wastila WB.  1995.  The future of the benzylisoquinolinium relaxants.. Acta Anaesthesiol Scand Suppl. 106:91-3.
1993
Lien CA, Gadalla F, Kudlak TT, Embree PB, Sharp GJ, Savarese JJ.  1993.  The effect of ondansetron on atracurium-induced neuromuscular blockade.. J Clin Anesth. 5(5):399-403.
1988
Ali HH, Savarese JJ, Embree PB, Basta SJ, Stout RG, Bottros LH, Weakly JN.  1988.  Clinical pharmacology of mivacurium chloride (BW B1090U) infusion: comparison with vecuronium and atracurium.. Br J Anaesth. 61(5):541-6.
1986
Scott RP, Savarese JJ, Basta SJ, Embree P, Ali HH, Sunder N, Hoaglin DC.  1986.  Clinical pharmacology of atracurium given in high dose.. Br J Anaesth. 58(8):834-8.
Savarese JJ.  1986.  Clinical relaxation: current controversy.. Can Anaesth Soc J. 33(3 Pt 2):S1-4.
deBros FM, Lai A, Scott R, deBros J, Batson AG, Goudsouzian N, Ali HH, Cosimi AB, Savarese JJ.  1986.  Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients.. Anesth Analg. 65(7):743-6.
1985
Scott RP, Savarese JJ, Basta SJ, Sunder N, Ali HH, Gargarian M, Gionfriddo M, Batson AG.  1985.  Atracurium: clinical strategies for preventing histamine release and attenuating the haemodynamic response.. Br J Anaesth. 57(6):550-3.
1983
Ali HH, Savarese JJ, Basta SJ, Sunder N, Gionfriddo M.  1983.  Evaluation of cumulative properties of three new nondepolarizing neuromuscular blocking drugs BW A444U, atracurium and vecuronium.. Br J Anaesth. 55 Suppl 1:107S-111S.
Basta SJ, Savarese JJ, Ali HH, Moss J, Gionfriddo M.  1983.  Histamine-releasing potencies of atracurium, dimethyl tubocurarine and tubocurarine.. Br J Anaesth. 55 Suppl 1:105S-106S.
1982
Basta SJ, Ali HH, Savarese JJ, Sunder N, Gionfriddo M, Cloutier G, Lineberry C, Cato AE.  1982.  Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant.. Anesth Analg. 61(9):723-9.